HIV-1 gp120 envelope glycoprotein — Drug Target

All drugs that target HIV-1 gp120 envelope glycoprotein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Viral vector vaccine

Phase 3 pipeline (1)

• ALVAC(2)120(B,MN)GNP (vCP1452) · National Institute of Allergy and Infectious Diseases (NIAID) · Viral vector vaccine · Immunology / Infectious Disease
  ALVAC(2)120(B,MN)GNP is a recombinant canarypox virus-based vaccine that expresses HIV-1 gp120 and other viral antigens to elicit cellular and humoral immune responses against HIV-1.